

IN THE CLAIMS:

Please cancel Claims 25, 31, 32 and 57-59 without prejudice to or disclaimer of the subject matter contained therein.

Please amend Claims 24, 30, 33, 35-38 and 60, and add new Claim 61 to read as follows:

24. (Currently Amended) An isolated peptide capable of generating a T cell response directed against telomerase, said peptide containing up to 25 amino acids and comprising the amino acid sequence SEQ ID NO:2 ~~an amino acid residue sequence selected from the group consisting of~~ ~~EARPALLTSRLRFIPK (SEQ ID NO:2);~~ ~~DGLRPIVNM DYVVGAR (SEQ ID NO:3);~~ ~~GVPEYGCVVNLRKTVVNF (SEQ ID NO:4);~~ ~~ILAKFLHWL (SEQ ID NO:9);~~ ~~ELLRSFFYV (SEQ ID NO:10);~~ ~~LMSVYVV ELLRSFFYVTE (SEQ ID NO:7);~~ ~~SEQ ID NOs: 5, 6, 12, 13, 16, and 19;~~ and the sequences set out in Table 1 and Table 2 herein.

25. (Cancelled)

26. (Withdrawn) A nucleic acid that encodes a peptide according to claim 24.

27. (Withdrawn) A pharmaceutical composition comprising at least one nucleic acid according to claim 26, and a pharmaceutically acceptable carrier or diluent.

28. (Withdrawn) The pharmaceutical composition according to claim 27, wherein the composition is for the treatment or prophylaxis of cancer.

29. (Withdrawn) The pharmaceutical composition according to claim 28, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer, malignant melanoma, leukemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

30. (Currently Amended) A ~~pharmaceutical~~ composition comprising at least one telomerase peptide according to claim 24, and a ~~pharmaceutically acceptable~~ carrier or diluent therefor.

31. (Cancelled)

32. (Cancelled)

33. (Currently Amended) A method of preparing a ~~pharmaceutical~~ peptide composition, comprising the step of mixing at least one telomerase peptide of claim 24 with a ~~pharmaceutically acceptable~~ carrier or diluent therefor.

34. (Withdrawn) A method of preparing a pharmaceutical composition, comprising the step of mixing at least one nucleic acid of claim 26 with a pharmaceutically acceptable carrier or diluent.

35. (Currently Amended) A ~~pharmaceutical~~ multi-peptide composition comprising:

- (a) at least one ~~telomerase~~ peptide according to claim 24,
- (b) at least one peptide not containing SEQ ID NO:2, but which is capable of inducing a T cell response directed against either (i) an oncogene protein or peptide, or (ii) a mutant tumor suppressor protein or peptide, and
- (c) a ~~pharmaceutically acceptable~~ carrier or diluent for the said peptides.

36. (Currently Amended) A method of preparing a ~~pharmaceutical~~ multi-peptide composition, comprising the step of forming a mixture of:

- (a) at least one ~~telomerase~~ peptide according to claim 24,
- (b) at least one peptide not containing SEQ ID NO:2, but which is capable of inducing a T cell response directed against either (i) an oncogene protein or peptide or (ii) a mutant tumor suppressor protein or peptide, and
- (c) a ~~pharmaceutically acceptable~~ carrier or diluent for the said peptides.

37. (Currently Amended) The ~~pharmaceutical~~ multi-peptide composition according to claim 35, wherein the oncogene protein or peptide is a mutant p21-ras protein or peptide, and the tumor suppressor protein or peptide is selected from the group consisting of a retinoblastoma protein or peptide and a p53 protein or peptide.

38. (Currently Amended) The method of preparing a ~~pharmaceutical~~ multi-peptide composition according to claim 36, wherein the oncogene protein or peptide is a

mutant p21-ras protein or peptide, and the tumor suppressor protein or peptide is selected from the group consisting of a retinoblastoma protein or peptide and a p53 protein or peptide.

39. (Withdrawn) A method of generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal, comprising the steps of:

- (a) taking a sample of T lymphocytes from a mammal, and
- (b) culturing the T lymphocyte sample in the presence of an amount of a telomerase peptide sufficient to generate telomerase-specific T lymphocytes, wherein the telomerase peptide comprises an amino acid residue sequence selected from the group consisting of: EARPALLTSRLRFIPK (SEQ ID NO:2), DGLRPIVNMDYVVGAR (SEQ ID NO:3), GVPEYGCVVNLKRTVVNF (SEQ ID NO:4), ILAKFLHWL (SEQ ID NO:9), ELLRSFFYV (SEQ ID NO:10), LMSVYVVELLRSFFYVTE (SEQ ID NO:7), SEQ ID NOS: 5, 6, 12, 13, 16, and 19, and the sequences set out in Table 1 and Table 2 herein.

40. (Withdrawn) A telomerase-specific T lymphocyte generated by the method according to claim 39.

41. (Withdrawn) A pharmaceutical composition comprising a telomerase-specific T lymphocyte according to claim 40, and a pharmaceutically acceptable carrier or diluent.

42. (Withdrawn) The pharmaceutical composition according to claim 41, wherein the composition is for the treatment or prophylaxis of cancer.

43. (Withdrawn) The pharmaceutical composition according to claim 42, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer, malignant melanoma, leukemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

44. (Withdrawn) A method of treating a mammalian patient afflicted with cancer, comprising the step of administering to the patient an effective amount of the pharmaceutical composition according to claim 27.

45. (Withdrawn) The method of treatment according to claim 44, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer, malignant melanoma, leukemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

46. (Withdrawn) The method of treatment according to claim 44, wherein the cancer is colon cancer.

47. (Withdrawn) A method of vaccinating a mammalian patient in order to obtain resistance against cancer comprising the step of eliciting a T-cell response in the

patient by stimulating the patient's immune system *in vivo* or *ex vivo* with a telomerase peptide according to claim 24.

48. (Withdrawn) A method of treating a mammalian patient afflicted with cancer, comprising the step of administering to the patient an effective amount of the pharmaceutical composition according to claim 30.

49. (Withdrawn) A method of treating a mammalian patient afflicted with cancer, comprising the step of administering to the patient an effective amount of the pharmaceutical composition according to claim 35.

50. (Withdrawn) A method of treating a mammalian patient afflicted with cancer, comprising the step of administering to the patient an effective amount of the pharmaceutical composition according to claim 41.

51. (Withdrawn) The method of treatment according to claim 48, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer, malignant melanoma, leukemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

52. (Withdrawn) The method of treatment according to claim 49, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, pancreatic

cancer, colorectal cancer, lung cancer, malignant melanoma, leukemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

53. (Withdrawn) The method of treatment according to claim 50, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer, malignant melanoma, leukemias, lymphomas, ovarian cancer, cervical cancer and biliary tract carcinomas.

54. (Withdrawn) The method of treatment according to claim 48, wherein the cancer is colon cancer.

55. (Withdrawn) The method of treatment according to claim 49, wherein the cancer is colon cancer.

56. (Withdrawn) The method of treatment according to claim 50, wherein the cancer is colon cancer.

57. (Cancelled)

58. (Cancelled)

59. (Cancelled)

60. (Currently Amended) ~~The peptide of claim 58, wherein the~~ An isolated peptide ~~consists~~ consisting of the amino acid ~~residue~~ sequence SEQ ID NO:2.

61. (New) The peptide according to claim 24, wherein the T cell response induced is a cytotoxic T cell response.